Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor
	Acts as a drug target< (This gene does not contain this module)

Gene: STAT1

Summary for STAT1

Gene information	Gene symbol	STAT1
	Ensembl ID	ENSG00000115415
	Entrez ID	6772
	Gene name	signal transducer and activator of transcription 1
	Synonyms	ISGF-3\|STAT91
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: STAT1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.444418	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.261879	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.414261	1.33e-28
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	-0.281374	1.31e-15
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.289042	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	-0.650246	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.596435	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.479343	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.543541	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.395611	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.500083	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.497527	3.66e-37
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Mono/Macro	-0.63779	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD8+ T cells	-0.380344	7.96e-32
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.310423	2.62e-25
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.316506	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	post	CD8+ T cells	0.275478	3.38e-22
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.280849	1.74e-29
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	0.32178	3.30e-16
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.463363	4.99e-15
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.605299	1.62e-33
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.758666	2.72e-15
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD8+ T cells	0.400184	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD4+ T cells	0.621942	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	0.255762	1.92e-33
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	0.50868	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.347553	4.41e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	-1.17574	7.97e-14
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.704647	5.18e-21
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-0.320329	2.58e-06
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.544182	7.56e-05
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	0.464156	1.28e-41
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	0.29135	1.01e-23
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	0.578096	0.00e+00
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	0.356616	8.68e-24
GSE104987	MCF7 cell line	Cell line	Breast cancer	ER+ breast cancer	Targeted therapy	KDM5-C70	NA	Malignant cells	-0.439182	2.42e-26
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	0.42757	0.00e+00

Top

Expression of STAT1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to STAT1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating STAT1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
STAT1	hsa-miR-1252-5p	98.4208	NM_007315
STAT1	hsa-miR-4682	95.2883	NM_007315
STAT1	hsa-miR-4533	93.9939	NM_007315
STAT1	hsa-miR-4668-5p	93.9107	NM_139266
STAT1	hsa-miR-4697-3p	92.8567	NM_007315
STAT1	hsa-miR-4724-3p	92.2683	NM_007315
STAT1	hsa-miR-3658	91.5016	NM_007315
STAT1	hsa-miR-4762-3p	91.0344	NM_007315
STAT1	hsa-miR-511-5p	89.8339	NM_007315
STAT1	hsa-miR-6886-3p	89.7637	NM_007315
STAT1	hsa-miR-6883-3p	89.6912	NM_007315
STAT1	hsa-miR-450a-1-3p	89.2516	NM_139266
STAT1	hsa-miR-5688	89.1626	NM_007315
STAT1	hsa-miR-6124	87.9223	NM_139266
STAT1	hsa-miR-217-3p	87.6574	NM_139266
STAT1	hsa-miR-599	86.2338	NM_007315
STAT1	hsa-miR-495-3p	85.621	NM_007315
STAT1	hsa-miR-4501	85.0935	NM_007315
STAT1	hsa-miR-7978	84.9103	NM_007315
STAT1	hsa-miR-3148	83.5742	NM_007315
STAT1	hsa-miR-1253	82.2396	NM_007315
STAT1	hsa-miR-2681-5p	81.9618	NM_007315
STAT1	hsa-miR-6740-3p	80.4395	NM_007315

Page: 1

Top

Motifs and transcription factors (TFs) regulating STAT1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
STAT1	transfac_pro__M02933	ZBTB14 (inferredBy_Orthology).
STAT1	metacluster_45.6	E2F1; E2F1; E2F1; E2F1; E2F1; E2F2; E2F2; E2F2; E2F3; E2F3; E2F3; E2F4; E2F4 (directAnnotation). E2F2; E2F3 (inferredBy_Orthology).
STAT1	transfac_pro__M00652	NRF1 (directAnnotation).
STAT1	metacluster_22.25	NFE2L2 (directAnnotation).
STAT1	transfac_pro__M06232	ZNF234 (directAnnotation).
STAT1	metacluster_22.27	NFE2L2 (inferredBy_Orthology).
STAT1	metacluster_22.12	NFE2; NFE2L1 (directAnnotation).
STAT1	swissregulon__hs__RUNX2	RUNX2 (directAnnotation).
STAT1	metacluster_22.30	NFE2L2 (directAnnotation).
STAT1	transfac_pro__M05916	ZNF407 (directAnnotation).
STAT1	metacluster_70.19	POU1F1 (directAnnotation).
STAT1	metacluster_70.23	POU3F4 (directAnnotation).
STAT1	metacluster_137.2	ATF3; BACH2; BATF; BATF; BATF; BATF; BATF3; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOSB; FOSB; FOSB; FOSB; FOSB; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; INSM2; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; SMARCC1 (directAnnotation). ATF3; ATF3; BATF; FOS; FOSB; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUNB; JUND; JUND; JUND; JUND (inferredBy_Orthology).
STAT1	transfac_pro__M06741	ZNF70 (directAnnotation).
STAT1	transfac_pro__M01239	RELA (directAnnotation).
STAT1	transfac_pro__M04706	RELA (directAnnotation).
STAT1	transfac_pro__M05605	GATA6 (inferredBy_Orthology).
STAT1	yetfasco__TBP-TFIIA-TFIIB_1330	GTF2B; TBPL2 (inferredBy_Orthology).
STAT1	transfac_pro__M06807	SALL2 (inferredBy_Orthology).
STAT1	taipale_tf_pairs__TEAD4_ETV4_RCCGGAAATRCC_CAP	ETV4; TEAD4 (directAnnotation).
STAT1	metacluster_22.18	BACH2 (inferredBy_Orthology).
STAT1	metacluster_5.1	HIVEP1; HIVEP1; NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; NFKB2; NFKB2; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELB; RELB (directAnnotation). NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; REL; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELB; RELB; RELB (inferredBy_Orthology).
STAT1	taipale_tf_pairs__GCM1_CEBPB_MTRSGGGNNNNNNTTRCGYAAN_CAP	CEBPB; GCM1 (directAnnotation).
STAT1	transfac_pro__M06818	ZNF592 (inferredBy_Orthology).
STAT1	taipale_tf_pairs__CUX1_SOX15_NATCRATNNNNNNNAACAATRS_CAP_repr	CUX1; SOX15 (directAnnotation).
STAT1	transfac_pro__M06402	ZNF493 (directAnnotation).
STAT1	metacluster_155.35	FIZ1; ZNF322 (directAnnotation). ZNF322 (inferredBy_Orthology).
STAT1	metacluster_22.29	NFE2 (directAnnotation).
STAT1	tfdimers__MD00208	IRF1; LTF (directAnnotation).
STAT1	transfac_pro__M04858	THAP1 (directAnnotation).
STAT1	transfac_pro__M06841	ZNF507 (directAnnotation).
STAT1	kznf__PRDM1_modENCODE.1_ChIP-seq	PRDM1 (directAnnotation).
STAT1	hdpi__ETS1	ETS1 (directAnnotation).
STAT1	jaspar__MA0056.2	MZF1 (directAnnotation).
STAT1	jaspar__MA0776.1	MYBL1 (directAnnotation).
STAT1	transfac_pro__M05423	RREB1 (directAnnotation).
STAT1	transfac_pro__M05896	ZNF713 (directAnnotation).
STAT1	jaspar__MA1963.1	SATB1 (directAnnotation).
STAT1	taipale_cyt_meth__FOXO3_NTCCCCACACN_eDBD	FOXO3 (directAnnotation).
STAT1	transfac_pro__M06263	ZNF211 (directAnnotation).
STAT1	metacluster_70.14	POU2F3 (directAnnotation).
STAT1	metacluster_174.3	MBD2; NFYA; NFYB; NFYC; PBX3 (directAnnotation).
STAT1	metacluster_75.11	SCRT1; SCRT2 (directAnnotation).
STAT1	metacluster_75.12	SCRT1; SCRT2 (directAnnotation).
STAT1	metacluster_70.15	POU2F2 (directAnnotation).
STAT1	metacluster_174.2	CEBPZ; CEBPZ; DRAP1; FOS; FOXI1; FOXI1; HMGXB3; IRF3; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYB; NFYB; NFYB; NFYB; NFYB; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; PBX3; PBX3; SP2 (directAnnotation). NFYA; NFYA; NFYC; PBX1; PBX3 (inferredBy_Orthology).
STAT1	taipale_tf_pairs__GCM2_ELK1_NNRNGGGCGGAARTN_CAP	ELK1; GCM2 (directAnnotation).
STAT1	taipale_tf_pairs__GCM1_ELK1_RTGCGGGCGGAAGTN_CAP_2	ELK1; GCM1 (directAnnotation).
STAT1	transfac_pro__M04950	EGR1 (directAnnotation).
STAT1	transfac_pro__M04913	ZBTB7A (directAnnotation).

Page: 1 2 3 4 5

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

TF	motif	Expression	Cell type	Dataset	Timepoint
STAT1	transfac_pro__M00492	up	Malignant cells	GSE131984_JQ1Pal	NA
STAT1	metacluster_2.7	up	Malignant cells	GSE150930	NA
STAT1	metacluster_2.6	up	B cells	GSE169246_PacAteTissue	post
STAT1	metacluster_2.7	up	B cells	GSE169246_PacAteTissue	post
STAT1	metacluster_38.1	up	B cells	GSE169246_PacAteTissue	post
STAT1	metacluster_2.7	up	CD4+ T cells	GSE169246_PacAteTissue	post
STAT1	metacluster_2.7	up	CD8+ T cells	GSE169246_PacAteTissue	post
STAT1	metacluster_2.6	up	CD8+ T cells	GSE169246_PacAteTissue	post
STAT1	metacluster_2.6	up	CD4+ T cells	GSE169246_PacAteTissue	pre
STAT1	metacluster_2.6	down	Mono/Macro	GSE169246_PacAteTissue	pre
STAT1	metacluster_29.2	up	Mono/Macro	GSE169246_PacTissue	pre
STAT1	metacluster_2.6	down	Mono/Macro	GSE197268_Axi-cel	post
STAT1	metacluster_2.7	down	Mono/Macro	GSE197268_Axi-cel	post
STAT1	tfdimers__MD00336	down	CD8+ T cells	GSE197268_Axi-cel	pre
STAT1	tfdimers__MD00230	down	CD8+ T cells	GSE197268_Axi-cel	pre
STAT1	transfac_pro__M04721	down	CD8+ T cells	GSE197268_Axi-cel	pre
STAT1	metacluster_2.6	up	CD4+ T cells	GSE197268_Tisa-cel	post
STAT1	metacluster_2.7	up	CD4+ T cells	GSE197268_Tisa-cel	post
STAT1	tfdimers__MD00230	up	CD8+ T cells	GSE197268_Tisa-cel	post
STAT1	metacluster_2.6	up	CD8+ T cells	GSE197268_Tisa-cel	post
STAT1	tfdimers__MD00215	up	Mono/Macro	GSE197268_Tisa-cel	pre
STAT1	metacluster_29.2	up	Mono/Macro	GSE207422_Sin	post
STAT1	metacluster_2.6	down	B cells	GSE207422_Tor	post
STAT1	metacluster_2.7	down	B cells	GSE207422_Tor	post
STAT1	cisbp__M11350	down	B cells	GSE207422_Tor	post
STAT1	tfdimers__MD00177	down	B cells	GSE207422_Tor	post
STAT1	metacluster_2.6	down	Mono/Macro	GSE207422_Tor	post
STAT1	metacluster_2.6	down	Mono/Macro	GSE207422_Tor	post
STAT1	metacluster_2.7	down	Mono/Macro	GSE207422_Tor	post
STAT1	tfdimers__MD00585	up	Neutrophils	GSE207422_Tor	post

Page: 1

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."